We note it has been about 6 months since the FDA minor deficiency letter for TEVA's generic enoxaparin. As additional time passes, we believe approval of TEVA's generic becomes more questionable.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.